Ovarian cancer: Current status and strategies for improving therapeutic outcomes

Ashwin Chandra, Cima Pius, Madiha Nabeel, Maya Nair, Jamboor K. Vishwanatha, Sarfraz Ahmad, Riyaz Basha

Research output: Contribution to journalReview article

Abstract

Of all the gynecologic tumors, ovarian cancer (OC) is known to be the deadliest. Advanced-stages of OC are linked with high morbidity and low survival rates despite the immense amount of research in the field. Shortage of promising screening tools for early-stage detection is one of the major challenges linked with the poor survival rate for patients with OC. In OC, therapeutic management is used with multidisciplinary approaches that includes debulking surgery, chemotherapy, and (rarely) radiotherapy. Recently, there is an increasing interest in using immunomodulation for treating OC. Relapse rates are high in this malignancy and averages around every 2-years. Further treatments after the relapse are more intense, increasing the toxicity, resistance to chemotherapy drugs, and financial burden to patients with poor quality-of-life. A procedure that has been studied to help reduce the morbidity rate involves pre-sensitizing cancer cells with standard therapy in order to produce optimal results with minimum dosage. Utilizing such an approach, platinum-based agents are effective due to their increased response to platinum-based chemotherapy in relapsed cases. These chemo-drugs also help address the issue of drug resistance. After conducting an extensive search with available literature and the resources for clinical trials, information is precisely documented on current research, biomarkers, options for treatment and clinical trials. Several schemes for enhancing the therapeutic responses for OC are discussed systematically in this review with an attempt in summarizing the recent developments in this exciting field of translational/clinical research.

Original languageEnglish
Pages (from-to)7018-7031
Number of pages14
JournalCancer Medicine
Volume8
Issue number16
DOIs
StatePublished - 1 Nov 2019

Fingerprint

Ovarian Neoplasms
Platinum
Drug Therapy
Therapeutics
Survival Rate
Clinical Trials
Morbidity
Recurrence
Neoplasms
Translational Medical Research
Immunomodulation
Research
Drug Resistance
Pharmaceutical Preparations
Radiotherapy
Biomarkers
Quality of Life

Keywords

  • biomarkers
  • clinical trials
  • ovarian cancer
  • ovarian cancer screening

Cite this

Chandra, Ashwin ; Pius, Cima ; Nabeel, Madiha ; Nair, Maya ; Vishwanatha, Jamboor K. ; Ahmad, Sarfraz ; Basha, Riyaz. / Ovarian cancer : Current status and strategies for improving therapeutic outcomes. In: Cancer Medicine. 2019 ; Vol. 8, No. 16. pp. 7018-7031.
@article{78f98279a0be4794bd3ea63fbb37678b,
title = "Ovarian cancer: Current status and strategies for improving therapeutic outcomes",
abstract = "Of all the gynecologic tumors, ovarian cancer (OC) is known to be the deadliest. Advanced-stages of OC are linked with high morbidity and low survival rates despite the immense amount of research in the field. Shortage of promising screening tools for early-stage detection is one of the major challenges linked with the poor survival rate for patients with OC. In OC, therapeutic management is used with multidisciplinary approaches that includes debulking surgery, chemotherapy, and (rarely) radiotherapy. Recently, there is an increasing interest in using immunomodulation for treating OC. Relapse rates are high in this malignancy and averages around every 2-years. Further treatments after the relapse are more intense, increasing the toxicity, resistance to chemotherapy drugs, and financial burden to patients with poor quality-of-life. A procedure that has been studied to help reduce the morbidity rate involves pre-sensitizing cancer cells with standard therapy in order to produce optimal results with minimum dosage. Utilizing such an approach, platinum-based agents are effective due to their increased response to platinum-based chemotherapy in relapsed cases. These chemo-drugs also help address the issue of drug resistance. After conducting an extensive search with available literature and the resources for clinical trials, information is precisely documented on current research, biomarkers, options for treatment and clinical trials. Several schemes for enhancing the therapeutic responses for OC are discussed systematically in this review with an attempt in summarizing the recent developments in this exciting field of translational/clinical research.",
keywords = "biomarkers, clinical trials, ovarian cancer, ovarian cancer screening",
author = "Ashwin Chandra and Cima Pius and Madiha Nabeel and Maya Nair and Vishwanatha, {Jamboor K.} and Sarfraz Ahmad and Riyaz Basha",
year = "2019",
month = "11",
day = "1",
doi = "10.1002/cam4.2560",
language = "English",
volume = "8",
pages = "7018--7031",
journal = "Cancer Medicine",
issn = "2045-7634",
publisher = "John Wiley and Sons Ltd",
number = "16",

}

Ovarian cancer : Current status and strategies for improving therapeutic outcomes. / Chandra, Ashwin; Pius, Cima; Nabeel, Madiha; Nair, Maya; Vishwanatha, Jamboor K.; Ahmad, Sarfraz; Basha, Riyaz.

In: Cancer Medicine, Vol. 8, No. 16, 01.11.2019, p. 7018-7031.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Ovarian cancer

T2 - Current status and strategies for improving therapeutic outcomes

AU - Chandra, Ashwin

AU - Pius, Cima

AU - Nabeel, Madiha

AU - Nair, Maya

AU - Vishwanatha, Jamboor K.

AU - Ahmad, Sarfraz

AU - Basha, Riyaz

PY - 2019/11/1

Y1 - 2019/11/1

N2 - Of all the gynecologic tumors, ovarian cancer (OC) is known to be the deadliest. Advanced-stages of OC are linked with high morbidity and low survival rates despite the immense amount of research in the field. Shortage of promising screening tools for early-stage detection is one of the major challenges linked with the poor survival rate for patients with OC. In OC, therapeutic management is used with multidisciplinary approaches that includes debulking surgery, chemotherapy, and (rarely) radiotherapy. Recently, there is an increasing interest in using immunomodulation for treating OC. Relapse rates are high in this malignancy and averages around every 2-years. Further treatments after the relapse are more intense, increasing the toxicity, resistance to chemotherapy drugs, and financial burden to patients with poor quality-of-life. A procedure that has been studied to help reduce the morbidity rate involves pre-sensitizing cancer cells with standard therapy in order to produce optimal results with minimum dosage. Utilizing such an approach, platinum-based agents are effective due to their increased response to platinum-based chemotherapy in relapsed cases. These chemo-drugs also help address the issue of drug resistance. After conducting an extensive search with available literature and the resources for clinical trials, information is precisely documented on current research, biomarkers, options for treatment and clinical trials. Several schemes for enhancing the therapeutic responses for OC are discussed systematically in this review with an attempt in summarizing the recent developments in this exciting field of translational/clinical research.

AB - Of all the gynecologic tumors, ovarian cancer (OC) is known to be the deadliest. Advanced-stages of OC are linked with high morbidity and low survival rates despite the immense amount of research in the field. Shortage of promising screening tools for early-stage detection is one of the major challenges linked with the poor survival rate for patients with OC. In OC, therapeutic management is used with multidisciplinary approaches that includes debulking surgery, chemotherapy, and (rarely) radiotherapy. Recently, there is an increasing interest in using immunomodulation for treating OC. Relapse rates are high in this malignancy and averages around every 2-years. Further treatments after the relapse are more intense, increasing the toxicity, resistance to chemotherapy drugs, and financial burden to patients with poor quality-of-life. A procedure that has been studied to help reduce the morbidity rate involves pre-sensitizing cancer cells with standard therapy in order to produce optimal results with minimum dosage. Utilizing such an approach, platinum-based agents are effective due to their increased response to platinum-based chemotherapy in relapsed cases. These chemo-drugs also help address the issue of drug resistance. After conducting an extensive search with available literature and the resources for clinical trials, information is precisely documented on current research, biomarkers, options for treatment and clinical trials. Several schemes for enhancing the therapeutic responses for OC are discussed systematically in this review with an attempt in summarizing the recent developments in this exciting field of translational/clinical research.

KW - biomarkers

KW - clinical trials

KW - ovarian cancer

KW - ovarian cancer screening

UR - http://www.scopus.com/inward/record.url?scp=85073965343&partnerID=8YFLogxK

U2 - 10.1002/cam4.2560

DO - 10.1002/cam4.2560

M3 - Review article

C2 - 31560828

AN - SCOPUS:85073965343

VL - 8

SP - 7018

EP - 7031

JO - Cancer Medicine

JF - Cancer Medicine

SN - 2045-7634

IS - 16

ER -